Vuong Trieu

CEO Vuong Trieu buys 255,000 shares (255.0K) at $0.04 across 3 transactions totaling $11,475.00

Vuong Trieu, the CEO, acquired 255,000 shares over 3 consecutive trading days (June 22–24, 2026) at a blended average of $0.04, adding to substantial existing holdings of 93.69M shares. His prior buys at this ticker show a documented pattern of strong 90-day returns: acquisitions on July 8–10, 2025 returned +849.0% to +851.0% over 30 days and +1520.0% to +1698.0% over 90 days. However, recent fundamentals raise significant concerns—annual revenue contracted -96.0% year-over-year to just $70.0K in the latest quarter, the company posted a net loss of $-2.2M, and the market cap stands at only $22.2M. The current stock price of $0.05 sits -54.6% from its 52-week high and has declined -13.9% over the past 30 days despite the insider's recent accumulation, suggesting headwinds may be outpacing any confidence the purchases signal.

CEO Vuong Trieu buys 335,759 shares at $0.04; prior 5 trades at OTLC all achieved +82.1% to +1870.0% 90d returns.

Vuong Trieu, Chairman and CEO, executed 2 separate purchases totaling 335,759 shares for $15,013.25 at $0.04/share on consecutive trading days (2026-06-15 and 2026-06-17), increasing holdings by 335,759 shares to 93,389,560 shares. His prior 5 trades at OTLC show a striking timing pattern: all achieved positive 90-day returns, ranging from +82.1% to +1870.0%. This insider's cross-ticker track record across 10 prior buys averages +549.8% 90-day return with a 100.00% win rate. The current stock is trading at $0.04 (down 63.6% from 52-week high and down 27.3% over 30 days), yet the CEO is accumulating shares despite the company's deteriorating fundamentals: revenue contracted 96.0% year-over-year, the latest quarter generated only $70,000.00 in revenue while posting a $-2,193,776.00 net loss. The purchase signals conviction from the insider most accountable for business results, even as operational and financial metrics have collapsed substantially.

OTLC CEO Trieu Vuong bought 198,737 shares in 3 transactions totaling $993.69 (blended avg $0.01); prior buys at ticker perfectly timed—5 of 5 generated 90-day gains (26.9%–106.8%)

Trieu Vuong, Chairman and CEO, executed 3 separate purchases totaling 198,737 shares for $993.69 over July 8–10, 2025, at a blended average price of $0.01—significantly below the current price of $0.05. His same-ticker history at OTLC reveals a striking pattern: all 5 prior buys at this company were well-timed, with 90-day returns ranging from 26.9% to 106.8%. This filing continues that pattern at a stock now trading -28.6% from its 52-week high and down -3.0% over 90 days. However, the company's fundamentals present a counterweight: annual revenue declined -96.0% year-over-year (to $70,000.00 in the latest quarter), net income is negative at $-298,716.00 for the most recent fiscal year, and the market cap is $20,414,622.50. The CEO's repetitive purchasing—now 6 acquisitions at this ticker in recent months—occurs in a severely distressed operating environment, making the timing-based signal less conclusive than the prior track record alone would suggest.

CEO Trieu Vuong buys 346,844 shares at $0.03 across 3 trades; prior 4 OTLC buys all showed positive 90d returns

Trieu Vuong (Chairman and CEO) executed 3 open-market purchases totaling 346,844 shares for $9,711.63 at $0.03 per share over three consecutive trading days (Jan 29–31, 2025), increasing holdings by 0.4% to 93.19M shares. His prior trading history at Oncotelic is notable: across 5 distinct prior trades at this ticker, 4 of the 4 measurable buys achieved positive 90-day returns, ranging from +23.1% to +42.4%, indicating a pattern of well-timed entry points. Against current fundamentals, the company generated only $70,000 in quarterly revenue with a net loss of $3.3M and annual revenue declined 96.0%, yet the stock has fallen -14.3% over 30 days and -9.1% over 90 days from current levels. The timing pattern and recent price weakness warrant monitoring of whether this incremental accumulation at depressed levels continues the CEO's historical track record of entry timing at this specific ticker.

Oncotelic CEO Trieu Vuong bought 298,499 shares at $0.03 amid -96.0% annual revenue decline and $-3.3M loss.

Trieu Vuong, Chairman and CEO, purchased 298,499 shares at $0.03 on 2024-11-22, adding to holdings of 92.84M shares. The transaction occurs in a distressed context: Oncotelic posted quarterly revenue of $70.0K against a net loss of $-3.3M, with annual revenue growth of -96.0% year-over-year, indicating the company is severely unprofitable and experiencing near-total revenue collapse. Vuong's prior buys at this same ticker show a 4-of-5 pattern of 90-day gains (ranging +20.0% to +42.4% for the three most recent buys), though his cross-ticker record is more modest at +6.4% average 90d return. The stock is currently -25.0% from its 52-week high and down -14.3% over 30 days, positioning this purchase against recent momentum loss. Given the magnitude of operational deterioration and the micro-cap market cap of $12.2M, this insider acquisition warrants observation for what the CEO's continued commitment may (or may not) signal about the company's near-term viability.

CEO Trieu Vuong purchases 500,000 shares of OTLC at $0.02; stock down 50.0% from 52-week high amid revenue collapse (-96.0% YoY).

Trieu Vuong, Chairman and CEO of Oncotelic Therapeutics, purchased 500,000 shares at $0.02, bringing his holdings to 92,544,217 shares. The company faces severe headwinds: quarterly revenue stands at $70,000.00 with a net loss of $-209,837.00, and annual revenue growth contracted by -96.0% year-over-year. The stock is trading at -50.0% from its 52-week high and down -27.5% over the past 30 days. Notably, among his prior five purchases at this same ticker, timing outcomes were mixed—3 of 5 achieved positive 90-day returns, but the two most recent OTLC buys (2023-06-14 and 2023-05-26) resulted in negative 90-day returns of -9.5% and -19.4% respectively. This purchase follows a consistent pattern of accumulation at a distressed valuation, but the deteriorating financial metrics and recent underperformance of prior buys at this ticker present material execution risk.